BRAF and melanoma: A recent study has shown that MLK1–4 are enzymatically capable of RAF-independent MEK phosphorylation which, ultimately, can lead to reactivation of ERK signaling in melanoma cells with acquired resistance to a B-Raf inhibitor (Vemurafenib) in B-Raf V600E tumors [30].